跳到正文
原文
Regulatory Affairs Professionals Society· @RAPSorg · X·· 20 天前精选AI 评分75
AI 导读

FDA于周二发布指南草案,提出对个体化基因编辑产品的拟议监管方式,涵盖在单一新药临床试验申请(IND)下开发多个产品变体的情形。该草案面向个体化基因编辑产品的监管路径公开征求意见。

推荐理由

FDA就个体化基因编辑产品的监管路径发布征求意见稿,涉及单一IND下多产品变体的管理方式。

正文

FDA on Tuesday issued draft guidance laying out its proposed regulatory approach to overseeing individualized gene editing products, including those that feature multiple product variants developed under a single investigational new drug application.

https://hubs.la/Q04Czr130

来源:Regulatory Affairs Professionals Society · x.com